Literature DB >> 31176504

Identification of the rs9277534 HLA-DP expression marker by next generation sequencing for the selection of unrelated donors for hematopoietic cell transplantation.

Gansuvd Balgansuren1, Lois Regen2, Maggie Sprague2, Nakita Shelton2, Effie Petersdorf3, John A Hansen4.   

Abstract

Mismatching of an unrelated donor against a high-expression HLA-DPB1 recipient allele is associated with a high risk of graft-versus-host disease and mortality. The Seattle Cancer Care Alliance (SCCA) and Fred Hutchinson Cancer Research Center transplant program employs an algorithm to match for HLA-A, B, C, DRB1, DQB1 and DPB1 alleles (12/12) and to avoid, whenever possible, donor mismatching against a recipient high-expression HLA-DPB1 allele. HLA-DPB1 expression is associated with the rs9277534 A/G polymorphism located in the 3'UTR of the HLA-DPB1 gene. Next generation sequencing of HLA-DPB1 using the Illumina TruSight HLA V2 Sequencing Panel and Conexio Assign software analyses provides information on rs9277534 variants without the need for any additional SNP testing. Here we present the molecular location of rs9277534 in NGS data and discuss the challenges to resolve HLA-DPB1 ambiguities.
Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HLA-DPB1 expression marker; NGS; SNP rs9277534

Mesh:

Substances:

Year:  2019        PMID: 31176504     DOI: 10.1016/j.humimm.2019.05.010

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  1 in total

1.  Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.

Authors:  Effie W Petersdorf; Mats Bengtsson; Dianne De Santis; Valerie Dubois; Katharina Fleischhauer; Ted Gooley; Mary Horowitz; J Alejandro Madrigal; Mari Malkki; Caroline McKallor; Yasuo Morishima; Machteld Oudshoorn; Stephen R Spellman; Jean Villard; Phil Stevenson; Mary Carrington
Journal:  J Clin Oncol       Date:  2020-06-01       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.